Tranexamic acid for gastrointestinal bleeding: can a reduction in the risk of death be discounted? A systematic review and meta-analysis of individual patient data from 64 724 bleeding patients.

Ker, Katharine; Mansukhani, Raoul; Shakur-Still, Haleema; Arribas, Monica; Beaumont, Danielle; Roberts, Ian

Ker, Katharine; Mansukhani, Raoul; Shakur-Still, Haleema; Arribas, Monica; Beaumont, Danielle; Roberts, Ian.

Afiliación

Ker K; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK katharine.ker@lshtm.ac.uk.
Mansukhani R; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK.
Shakur-Still H; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK.
Arribas M; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK.
Beaumont D; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK.
Roberts I; Global Health Trials Group, Clinical Trials Unit, LSHTM, London, UK.

BMJ Open ; 13(2): e059982, 2023 02 22.

Article en En | MEDLINE | ID: mdl-36813490

Asunto(s)

Antifibrinolíticos; Ácido Tranexámico; Enfermedades Vasculares; Embarazo; Femenino; Humanos; Hemorragia Gastrointestinal

Palabras clave

gastroenterology; haematology; obstetrics; statistics & research methods; trauma management

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Ácido Tranexámico / Enfermedades Vasculares / Antifibrinolíticos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: BMJ Open Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google